Digital biomarkers are becoming increasingly important in clinical development as sponsors seek more sensitive, objective, and patient-centered ways to measure treatment effects.
Advances in wearable sensors, remote monitoring technologies, and digital health platforms have created new opportunities to capture real-world data continuously rather than relying solely on episodic clinic visits.
For sponsors preparing regulatory submissions, however, collecting digital data is only the beginning. The true challenge lies in transforming sensor-generated information into digital biomarkers that are scientifically valid, clinically meaningful, and acceptable to regulators.
Building FDA-ready measures requires a structured approach that combines technology selection, analytical rigor, clinical validation, and regulatory planning.
This article explores how sponsors develop digital biomarkers for clinical trials and what it takes to create measures that support regulatory decision-making.
Examples of digital biomarkers include:
- Walking speed measured through wearable sensors
- Sleep quality metrics derived from actigraphy devices
- Respiratory patterns collected through connected monitoring systems
- Heart rate variability measurements captured through wearable technologies
- Physical activity measures that reflect disease progression or treatment response
What are Digital Biomarkers?
Digital biomarkers are objective, quantifiable physiological or behavioral measures. These are collected through digital devices such as wearable sensors, smartphones, connected medical devices, or other digital health technologies.
Unlike traditional biomarkers, which may rely on laboratory tests, imaging studies, or biological samples, digital biomarkers are often derived from continuously collected real-world data. These measurements can provide insight into how patients function in their everyday environments rather than only during scheduled clinical assessments.
In clinical research, digital biomarkers help sponsors assess health status, monitor disease progression, evaluate treatment effectiveness, and better understand patient experience.
As regulatory agencies encourage innovation in patient-focused drug development, digital biomarkers are becoming an increasingly valuable component of modern clinical trials.
Why Digital Biomarkers Matter in Clinical Development?
Digital biomarkers offer advantages that traditional clinical assessments often cannot provide. Many conventional endpoints rely on infrequent site visits or subjective reporting.
While these measures remain important, they may not fully capture fluctuations in symptoms or real-world functioning between visits. Digital biomarkers help address these limitations by enabling continuous or high-frequency monitoring.
This approach can generate a more comprehensive picture of patient health while improving sensitivity to meaningful changes over time. Several factors are driving sponsor interest in digital biomarkers. Let us take a closer look at these factors.
Improved Sensitivity to Change
Continuous monitoring often captures subtle changes that may be missed through periodic assessments. This can be particularly valuable in therapeutic areas where disease progression occurs gradually or where treatment effects may be difficult to detect using conventional measures.
Enhanced Patient Centricity
Patient-focused drug development emphasizes outcomes that reflect experiences meaningful to patients. Digital biomarkers can capture aspects of daily life such as mobility, sleep, physical function, and activity patterns that are directly relevant to how patients feel and function.
Real World Evidence Generation
Healthcare decision makers increasingly value evidence that reflects real-world patient experiences. Digital biomarkers enable data collection in natural environments, yielding a more representative understanding of treatment impact.
Greater Operational Efficiency
Remote data collection can reduce participant burden while increasing data density. This may support decentralized clinical trial models and improve study accessibility for participants who face challenges attending frequent site visits.
These advantages explain why digital biomarkers are becoming a strategic priority across many therapeutic areas.
Understanding the FDA Perspective on Digital Biomarkers
Sponsors developing digital biomarkers must recognize that regulatory acceptance depends on evidence and not technology alone. The FDA has consistently emphasized that digital measures should be fit for purpose and supported by adequate validation.
Regulators are primarily interested in whether a measure accurately captures the concept it is intended to assess and whether it provides meaningful information for decision-making. A sophisticated sensor does not automatically create a valid digital biomarker.
Instead, sponsors must demonstrate that the measurement is reliable, interpretable, and clinically relevant within its intended context of use. When evaluating digital biomarkers, regulators generally focus on several key questions, such as:
- What concept is being measured?
- Why is that concept clinically meaningful?
- Does the technology accurately capture the intended measurement?
- Is the measure reliable and reproducible?
- Does the measure reflect outcomes important to patients?
- Is there sufficient evidence to support its intended use?
Answering these questions requires a structured development and validation strategy.
How Sponsors Build FDA-Ready Digital Biomarkers?
Developing submission-ready digital biomarkers is a multi-stage process that extends well beyond device deployment. Successful programs typically follow a framework that aligns technology, science, clinical relevance, and regulatory expectations. Here is a step-by-step process on how to build FDA-ready digital biomarkers.
Step 1: Define the Clinical Concept of Interest
The development process begins by identifying the concept that matters most to patients, clinicians, and regulators. Sponsors must determine what aspect of health, functioning, or disease progression they intend to measure. It can be done by markers like:
- Walking ability in neurological disease
- Sleep disruption in respiratory disorders
- Physical activity limitations in chronic conditions
- Recovery following medical interventions
A clearly defined concept of interest establishes the foundation for all subsequent development activities. Without this clarity, even technically sophisticated measures may fail to demonstrate clinical value.
Step 2: Select Appropriate Digital Measurement Technologies
Once the concept of interest has been established, sponsors must identify technologies capable of measuring it effectively. Technology selection involves much more than comparing device specifications.
Sponsors should evaluate measurement capabilities and performance characteristics. They should look into patient usability and data quality. These measures can help sponsors determine their perational feasibility and scalability across study populations.
The chosen technology must align with both scientific objectives and practical trial requirements. Organizations that specialize in digital measurement science often help sponsors evaluate technologies based on evidence rather than marketing claims.
Step 3: Establish Analytical Validity
Analytical validity demonstrates that a digital biomarker accurately measures its intended target. This phase focuses on the relationship between raw sensor data and the resulting digital measure. Sponsors must evaluate:
- Accuracy
- Precision
- Reliability
- Signal processing methods
- Algorithm performance
- Data quality controls
Analytical validation ensures that the measure performs consistently across different environments, populations, and usage scenarios. Without analytical validity, clinical interpretation becomes difficult and regulatory confidence may be limited.
Step 4: Demonstrate Clinical Validity
Clinical validity establishes the relationship between a digital biomarker and meaningful health outcomes. This step is often one of the most important components of the development process.
Sponsors must demonstrate that the measure reflects disease status, progression, treatment response, or other clinically relevant outcomes. Clinical validation may involve correlation with established clinical measures, natural history studies, and longitudinal analyses.
These lead to patient-centered outcome assessments, assisting clinical expert evaluation. The goal is to show that changes in the digital biomarker correspond to meaningful changes in patient health.
Step 5: Build Evidence for Regulatory Acceptance
Regulatory readiness requires a comprehensive evidence package. Sponsors must document how the digital biomarker was developed, validated, and implemented throughout the clinical program.
A robust evidence package typically includes scientific rationale, technology evaluation data, and analytical validation findings. The clinical validation results lead to statistical analysis plans. Hence, it can build risk management documentation and participant usability assessments.
The strength of this evidence often determines whether a digital biomarker can support regulatory discussions and submission activities.
Common Challenges When Developing Digital Biomarkers
Although digital biomarkers offer significant potential, development programs frequently encounter obstacles. Recognizing these challenges early can help sponsors avoid delays and improve the likelihood of success.
Defining Clinically Meaningful Outcomes
One of the most common challenges involves identifying outcomes that matter to patients and healthcare providers. Measures that are technically impressive but lack clinical relevance may struggle to gain regulatory acceptance.
Managing Complex Data Streams
Wearable sensors and connected technologies generate enormous amounts of information. Sponsors must develop processes for data collection, storage, quality control, processing, and analysis. Without appropriate infrastructure, large datasets can become difficult to manage and interpret.
Validation Requirements
Validation remains one of the most resource-intensive aspects of digital biomarker development. Generating sufficient evidence requires careful planning, multidisciplinary collaboration, and ongoing evaluation.
Regulatory Uncertainty
Although regulatory guidance continues to evolve, expectations may vary depending on the therapeutic area, context of use, and intended application. Early engagement with experienced partners can help sponsors navigate these complexities more effectively.
The Role of Specialized Digital Measurement Expertise
Building FDA-ready digital biomarkers requires expertise that spans clinical science, sensor technology, biostatistics, data science, and regulatory strategy. Many sponsors find that these capabilities do not exist within a single internal team.
As a result, organizations increasingly collaborate with specialized partners that focus on digital measurement and wearable sensor research. These partners can support:
- Digital biomarker strategy
- Sensor selection
- Endpoint development
- Validation planning
- Statistical analysis
- Regulatory preparation
- Evidence generation
By integrating expertise across multiple disciplines, sponsors can accelerate development while reducing implementation risks. This collaborative approach is particularly valuable when digital biomarkers are expected to support key clinical endpoints or regulatory submissions.
The Future of Digital Biomarkers in Clinical Trials
The role of digital biomarkers is expected to expand significantly over the coming years. Advances in wearable technologies, machine learning, artificial intelligence, and remote monitoring are creating opportunities to measure health in increasingly sophisticated ways.
At the same time, regulatory agencies continue to engage with industry stakeholders to establish frameworks that support innovation while maintaining scientific rigor. Future developments in the area could lead to more sensitive measures of disease progression.
This can result in an expanded use of digital endpoints in pivotal trials with a greater integration of artificial intelligence-driven analytics. The enhanced patient-focused outcome assessment can result in broader adoption across therapeutic areas.
As these innovations emerge, sponsors that invest in rigorous development and validation strategies will be best positioned to realize the full value of digital biomarkers.
Advancing Digital Biomarker Development with VivoSense
Digital biomarkers have the potential to transform clinical research by providing more sensitive, objective, and patient-centered measures of health and treatment response. However, achieving regulatory readiness requires a deliberate strategy.
This combines scientific rigor, validation expertise, and a deep understanding of digital measurement. VivoSense helps sponsors develop and validate digital biomarkers that support clinical development and regulatory decision-making.
Through expertise in wearable sensors, digital endpoints, analytical validation, and evidence generation, VivoSense supports sponsors seeking to build FDA-ready measures. The goal is to ensure the measures are both scientifically robust and clinically meaningful.
Explore VivoSense resources on digital biomarkers, wearable sensor validation, and digital endpoint development to learn how specialized expertise can support your next clinical program.
Frequently Asked Questions
What is the difference between a biomarker and a digital biomarker?
A traditional biomarker is typically derived from laboratory testing, imaging, or biological samples. A digital biomarker is generated from data collected through digital technologies such as wearable sensors, smartphones, or connected health devices.
Can digital biomarkers be used as primary endpoints in clinical trials?
Yes, digital biomarkers can potentially support primary endpoints when sufficient validation evidence demonstrates that the measure is reliable, clinically meaningful, and fit for its intended use.
What evidence does the FDA expect for digital biomarkers?
The FDA generally expects evidence supporting analytical validity, clinical validity, and the measure’s relevance within its intended context of use. Requirements vary depending on the specific application.
Which therapeutic areas use digital biomarkers most frequently?
Digital biomarkers are increasingly used in neurology, respiratory disease, cardiology, sleep medicine, oncology, rare disease research, and musculoskeletal conditions, where continuous monitoring can provide valuable insights.
How long does it take to develop a validated digital biomarker?
Development timelines vary considerably depending on the complexity of the measure, available evidence, validation requirements, and regulatory objectives. Many programs require multiple phases of evidence generation before regulatory use.